Dermatol. praxi. 2022;16(2):85-87 | DOI: 10.36290/der.2022.016

Choice of biological therapy in terms of psoriasis comorbidities

MUDr. Jan Hugo
Dermatovenerologická klinika FNKV a 3. LF UK, Praha

Patients with psoriasis suffer from a variety of comorbidities, arising from both direct and indirect causes. These comorbidities are very heterogeneous, ranging from metabolic, to cardiovascular, to other autoimmune diseases. Some comorbidities may also be drug-induced. Therefore, the choice of systemic therapy, including biologic therapy, must take into account possible comorbidities, especially because of possible contraindications or, conversely, possible common therapeutic use

Keywords: psoriasis, comorbidities, biologic therapy, personalized medicine.

Published: June 7, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hugo J. Choice of biological therapy in terms of psoriasis comorbidities. Dermatol. praxi. 2022;16(2):85-87. doi: 10.36290/der.2022.016.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl 2(Suppl 2):ii14-7. Go to original source... Go to PubMed...
    2. Alenius GM, Stenberg B, Stenlund H, et al. Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire. J Rheumatol. 2002;29(12):2577-2582. Go to PubMed...
    3. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700-712. Go to original source... Go to PubMed...
    4. Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019;71(1):5-32. Go to original source... Go to PubMed...
    5. Gisondi P, Ferrazzi A, Girolomoni G. Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat. 2010;18(4):297-304. Go to PubMed...
    6. Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840-848. Go to original source... Go to PubMed...
    7. Gisondi P. Does systemic treatment of psoriasis reduce the risk of comorbidities? Br J Dermatol. 2020;182(4):823-824. Go to original source... Go to PubMed...
    8. Singh S, Facciorusso A, Singh AG, et al. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS One. 2018;13(5):e0195123. Go to original source... Go to PubMed...
    9. Patsalos O, Dalton B, Leppanen J, et al. Impact of TNF-α Inhibitors on Body Weight and BMI: A Systematic Review and Meta-Analysis. Front Pharmacol. 2020;11:481. Go to original source... Go to PubMed...
    10. Patel RV, Shelling ML, Prodanovich S, et al. Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature. J Gen Intern Med. 2011;26(9):1036-1049. Go to original source... Go to PubMed...
    11. Shi LQ, Lian N, Sun JT, et al. Association between the systemic treatment of psoriasis and cardiovascular risk. Chin Med J (Engl). 2021;134(5):518-520. Go to original source... Go to PubMed...
    12. Qureshi AA, Choi HK, Setty AR, et al. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009;145:379-382. Go to original source... Go to PubMed...
    13. Takeshita J, Wang S, Shin DB, et al. Effect of psoriasis severity on hypertension control: a population‑based study in the United Kingdom. JAMA Dermatol 2015;151:161-169. Go to original source... Go to PubMed...
    14. Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015;74:480-489. Go to original source... Go to PubMed...
    15. Hong JR, Jeong H, Kim H, et al. The potential impact of systemic anti-inflammatory therapies in psoriasis on major adverse cardiovascular events: a Korean nationwide cohort study. Sci Rep. 2021; 11, 8588. Go to original source... Go to PubMed...
    16. Kleinbongard P, Schulz R, Heusch G. TNFalpha in myocardial ischemia/reperfusion, remodeling and heart failure. Heart Fail Rev. 2011;16:49-69. Go to original source... Go to PubMed...
    17. Bozkurt B, Torre-Amione G, Warren MS, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 2001;103:1044-1047. Go to original source... Go to PubMed...
    18. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20:757-790. Go to original source... Go to PubMed...
    19. Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol. 2009;23:561-565. Go to original source... Go to PubMed...
    20. Ellinghaus D, Ellinghaus E, Nair RP, et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet. 2012;90:636-647. Go to original source... Go to PubMed...
    21. Fauny M, Moulin D, D'Amico F, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis. 2020;79(9):1132-1138. Go to original source... Go to PubMed...
    22. Wu JJ, Feldman SR, Koo J, et al. Epidemiology of mental health comorbidity in psoriasis. J Dermatolog Treat. 2018;29(5):487-495. Go to original source... Go to PubMed...
    23. Esposito M, Saraceno R, Giunta A, et al. An Italian study on psoriasis and depression. Dermatology. 2006;212(2): 123-127. Go to original source... Go to PubMed...
    24. Kurd SK, Troxel AB, Crits-Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891-895. Go to original source... Go to PubMed...
    25. Fleming P, Roubille C, Richer V, et al. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2015;29(6):1063-1070.Další literatura u autora a na www.dermatologiepropraxi.cz Go to original source... Go to PubMed...
    26. Lebwohl MG, Papp KA, Marangell LB, et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78(1):81-89.e85 Go to original source... Go to PubMed...
    27. Beck KM, Koo J. Brodalumab for the treatment of plaque psoriasis: up-to-date. Expert Opin Biol Ther. 2019;19(4):287-292. Go to original source... Go to PubMed...
    28. Kridin K, Shani M, Schonmann Y, et al. Psoriasis and Hidradenitis Suppurativa: A Large-scale Population-based Study. J Am Acad Dermatol. 2018 Nov 28:S0190-9622(18)32962-1. Go to original source... Go to PubMed...
    29. Choi E, Ooi XT, Chandran NS. Hidradenitis suppurativa in pediatric patients. J Am Acad Dermatol. 2022;86(1):140-147. Go to original source... Go to PubMed...
    30. Silfvast-Kaiser AS, Homan KB, Mansouri B. A narrative review of psoriasis and multiple sclerosis: links and risks. Psoriasis (Auckl). 2019;9:81-90. Go to original source... Go to PubMed...
    31. Kaltsonoudis E, Voulgari PV, Konitsiotis S, et al. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev. 2014;13(1):54-58. Go to original source... Go to PubMed...
    32. Kolbinger F, Huppertz C, Mir A, et al. IL-17A and multiple sclerosis: signaling pathways, producing cells and target cells in the central nervous systém; Curr Drug Targets. 2016;17 (16):1882-1893. Go to original source... Go to PubMed...
    33. Hugo J. Léčba secukinumabem u pacienta se souběhem těžké formy psoriázy a roztroušené sklerózy. Acta Medicinae. 2019;13:56-58.

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.